These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 2099131

  • 1. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
    Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H.
    Arch Int Pharmacodyn Ther; 1990; 308():123-36. PubMed ID: 2099131
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K, Tomioka K.
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 5. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 6. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H, Hara H, Suzuki T, Takahashi T, Takeuchi M, Matsuhisa A, Saito M, Yamada T, Tomioka K, Mase T.
    Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1659-64. PubMed ID: 9353894
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 13. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

  • 14. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
    Handley DA, Van Valen RG, Melden MK, Houlihan WJ, Saunders RN.
    J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958
    [Abstract] [Full Text] [Related]

  • 15. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.